Vaziri N, Shakourifar M, Sattari P, Sadeghi A, Sharifi M, Moghadas A
Iran J Pharm Res. 2025; 23(1):e156581.
PMID: 40066115
PMC: 11892750.
DOI: 10.5812/ijpr-156581.
Alam B, Akbari A, Ageed A, Duffy R
J Clin Med. 2025; 14(3).
PMID: 39941557
PMC: 11818147.
DOI: 10.3390/jcm14030885.
Watson M, Chambers P, Steventon L, Harmsworth King J, Ercia A, Shaw H
BMJ Oncol. 2025; 3(1):e000430.
PMID: 39886186
PMC: 11557724.
DOI: 10.1136/bmjonc-2024-000430.
Zhou Q, Yang H, Wang X, Wang L, Yan X, Zhang B
Eur J Clin Nutr. 2025; .
PMID: 39810008
DOI: 10.1038/s41430-025-01565-6.
Najah Q, Almosilhy N, Ghanm T
Eur J Clin Pharmacol. 2024; 81(2):269-278.
PMID: 39680077
DOI: 10.1007/s00228-024-03789-0.
Prospective study of once-daily accelerated partial breast irradiation using 3-dimensional conformal external beam radiotherapy for Japanese women: 12-year outcomes, toxicity, and cosmesis.
Takahashi K, Kagami Y, Yoshimura R, Morota M, Murakami N, Nakamura S
Breast Cancer. 2024; 32(1):197-207.
PMID: 39630209
PMC: 11717833.
DOI: 10.1007/s12282-024-01650-x.
Radiofrequency Ablation Therapy versus Stereotactic Body Radiation Therapy for Naive Hepatocellular Carcinoma (≤5cm): A Retrospective Multi-Center Study.
Sun J, Li W, He W, Yang Y, Duan L, Su T
J Hepatocell Carcinoma. 2024; 11:2199-2210.
PMID: 39558967
PMC: 11571075.
DOI: 10.2147/JHC.S488138.
Correlation of CTCAE and patient-reported breast radiation dermatitis symptom scores.
Rajeswaran T, Gojsevic M, Zhang L, Kennedy S, Karam I, Ding K
Support Care Cancer. 2024; 32(12):801.
PMID: 39556198
DOI: 10.1007/s00520-024-09018-9.
The benefit and risk of addition of chemotherapy to EGFR tyrosine kinase inhibitors for EGFR-positive non-small cell lung cancer patients with brain metastases: a meta-analysis based on randomized controlled trials.
Chen Z, Fu X, Zhu L, Wen X, Zhang S
Front Oncol. 2024; 14:1448336.
PMID: 39497717
PMC: 11532100.
DOI: 10.3389/fonc.2024.1448336.
Characterization of renal injury in non-squamous non-small cell lung cancer patients treated with pemetrexed: A single-center retrospective study.
Wu Y, Miao K, Chen M, Xu Y, Zhong W, Wang H
Thorac Cancer. 2024; 15(35):2474-2485.
PMID: 39468864
PMC: 11646693.
DOI: 10.1111/1759-7714.15470.
Para-aortic and pelvic lymphadenectomy in locally advanced cervical cancer with pelvic lymph node metastasis.
Jiang W, Zhong M, Wang S, Chen Y, Wang Y, Zeng S
World J Surg Oncol. 2024; 22(1):262.
PMID: 39350212
PMC: 11440892.
DOI: 10.1186/s12957-024-03540-0.
Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial.
Zhang J, Li M, Zhang K, Zheng A, Li G, Huang W
Cancer Commun (Lond). 2024; 44(10):1173-1188.
PMID: 39161079
PMC: 11483711.
DOI: 10.1002/cac2.12601.
Efficacy and safety of stem cell mobilization with etoposide +cytarabine plus G-CSF in poor mobilizers with relapsed or refractory lymphoma.
Zhu Z, Li X, Yuan X, Chen X, Lin T, Guo X
Front Immunol. 2024; 15:1439253.
PMID: 39091501
PMC: 11291192.
DOI: 10.3389/fimmu.2024.1439253.
Retrospective clinical study analysis of skin adverse reactions related to epidermal growth factor receptor inhibitors.
Qu J, Wen S, Lin Y, Lu H, Huang K, Maansson C
Transl Cancer Res. 2024; 13(6):3016-3030.
PMID: 38988913
PMC: 11231804.
DOI: 10.21037/tcr-24-486.
Benefits of adjuvant treatment with the Pingxiao capsule in patients with early breast cancer: A single‑center retrospective cohort study.
Wang S, Zheng C, Zhao L, Jiang H, Zheng X
Oncol Lett. 2024; 28(2):366.
PMID: 38933812
PMC: 11200151.
DOI: 10.3892/ol.2024.14499.
Acute skin toxicity and self-management ability among Chinese breast cancer radiotherapy patients: a qualitative study.
Lu X, Yin Y, Geng W, Liu L, Liu F, Zhang Z
Support Care Cancer. 2024; 32(6):394.
PMID: 38814489
PMC: 11139738.
DOI: 10.1007/s00520-024-08583-3.
Transarterial chemoembolization with I seed insertion for multifocal hepatocellular carcinoma.
Wang Y, Zhang Y, Li P, Bao L, Zhang W
Front Oncol. 2024; 14:1384293.
PMID: 38686190
PMC: 11056516.
DOI: 10.3389/fonc.2024.1384293.
Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis.
Wakabayashi N, Watanabe S, Abe T, Takenaka J, Hirata K, Kimura R
Ann Nucl Med. 2024; 38(7):553-562.
PMID: 38656630
DOI: 10.1007/s12149-024-01928-2.
Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study.
Han J, Sung P, Yoo J, Cho H, Lee S, Yang H
Front Oncol. 2024; 14:1372007.
PMID: 38482199
PMC: 10933027.
DOI: 10.3389/fonc.2024.1372007.
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.
Verkerk K, Geurts B, Zeverijn L, van der Noort V, Verheul H, Haanen J
Lancet Reg Health Eur. 2024; 39:100875.
PMID: 38464480
PMC: 10924203.
DOI: 10.1016/j.lanepe.2024.100875.